Trials / Completed
CompletedNCT07080190
Early Urine Alkalinization and N-Acetylcysteine Administration in the Management of Hair Dye (Paraphenylene Diamine) Intoxication
Assessment of the Role of Early Urine Alkalinization and N-Acetylcysteine Administration in the Management of Hair Dye (Paraphenylene Diamine) Intoxication
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- South Valley University · Academic / Other
- Sex
- All
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to determine the role of early urine alkalinization and N-acetylcysteine administration for the prevention of renal damage following hair dye intoxication
Detailed description
Paraphenylenediamine (PPD) is an organic compound with the formula C6H4(NH2). It is the derivative of aniline, which is a white substance that turns black on oxidation, called paraphenylaniline, which is soluble in hydrogen peroxide. Intoxication with hair dye (PPD) has become a standard method of intentional self-harm in some parts of Africa and Asia because it is cheap and readily available in the market(5). It can cause contact dermatitis in susceptible individuals. The glutathione (GSH) levels are depleted in PPD poisoning. The antioxidant GSH plays a vital role in the maintenance of cell viability, DNA replication, and the regulation of immune cell functions. N-acetylcysteine (NAC) acts as an antioxidant both directly as a glutathione substitute and indirectly as a precursor for glutathione.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Early N-Acetylcysteine | Patients received N-acetyl cysteine early (at admission) in the course of treatment of acute hair dye poisoning. |
| DRUG | Late N-Acetylcysteine | Patients received the standard treatment of N-acetyl cysteine after starting organ affection in the course of treatment of acute hair dye poisoning. |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2025-07-23
- Last updated
- 2025-07-23
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07080190. Inclusion in this directory is not an endorsement.